PMID- 19016769
OWN - NLM
STAT- MEDLINE
DCOM- 20081217
LR  - 20121115
IS  - 1349-7006 (Electronic)
IS  - 1347-9032 (Linking)
VI  - 99
IP  - 10
DP  - 2008 Oct
TI  - Optimal amount of monocyte chemoattractant protein-1 enhances antitumor effects 
      of suicide gene therapy against hepatocellular carcinoma by M1 macrophage 
      activation.
PG  - 2075-82
LID - 10.1111/j.1349-7006.2008.00951.x [doi]
AB  - Suicide gene therapy combined with chemokines provides significant antitumor 
      efficacy. Coexpression of suicide gene and monocyte chemoattractant protein-1 
      (MCP-1) increases antitumor effects in murine models of hepatocellular carcinoma 
      (HCC) and colon cancer. However, it is unclear whether the doses administered 
      achieved the maximum antitumor effects. We evaluated antitumor effects of various 
      amounts of recombinant adenovirus vector (rAd) expressing MCP-1 in the presence 
      of a suicide gene in a murine model of HCC. HCC cells were transplanted 
      subcutaneously into BALB/c nude mice, and transduced with a fixed amount of Ad-tk 
      harboring the suicide gene, HSV-tk, and various doses of Ad-MCP1 harboring MCP-1 
      (ratios of 1:1, 0.1:1, and 0.01:1 relative to Ad-tk). Growth of primary tumors 
      was suppressed when treated with Ad-tk plus Ad-MCP1 (1:1 and 1:0.1) as compared 
      with Ad-tk alone. The antitumor effects against tumor rechallenge tended to be 
      high in the Ad-tk plus Ad-MCP1 group (1:0.1). The effects were dependent on 
      production of Th1 type-cytokines. Delivery of an optimal amount of rAd expressing 
      MCP-1 enhanced the antitumor effects of suicide gene therapy against HCC by M1 
      macrophage activation, suggesting that this is a plausible form of cancer gene 
      therapy to prevent HCC progression and recurrence.
FAU - Tsuchiyama, Tomoya
AU  - Tsuchiyama T
AD  - Disease Control and Homeostasis, Graduate School of Medical Science, Kanazawa 
      University, Kanazawa, Japan.
FAU - Nakamoto, Yasunari
AU  - Nakamoto Y
FAU - Sakai, Yoshio
AU  - Sakai Y
FAU - Mukaida, Naofumi
AU  - Mukaida N
FAU - Kaneko, Shuichi
AU  - Kaneko S
LA  - eng
PT  - Journal Article
PL  - England
TA  - Cancer Sci
JT  - Cancer science
JID - 101168776
RN  - 0 (Chemokine CCL2)
SB  - IM
MH  - Adenoviridae/genetics
MH  - Animals
MH  - Carcinoma, Hepatocellular/genetics/*therapy
MH  - Cell Line, Tumor
MH  - Chemokine CCL2/*genetics
MH  - Disease Models, Animal
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Genes, Transgenic, Suicide/genetics
MH  - Genetic Therapy/*methods
MH  - Genetic Vectors
MH  - Humans
MH  - Immunohistochemistry
MH  - Liver Neoplasms, Experimental/genetics/*therapy
MH  - Macrophage Activation/*genetics
MH  - Macrophages, Peritoneal/immunology
MH  - Male
MH  - Mice
MH  - Mice, Nude
MH  - Xenograft Model Antitumor Assays
EDAT- 2008/11/20 09:00
MHDA- 2008/12/18 09:00
CRDT- 2008/11/20 09:00
PHST- 2008/11/20 09:00 [pubmed]
PHST- 2008/12/18 09:00 [medline]
PHST- 2008/11/20 09:00 [entrez]
AID - CAS951 [pii]
AID - 10.1111/j.1349-7006.2008.00951.x [doi]
PST - ppublish
SO  - Cancer Sci. 2008 Oct;99(10):2075-82. doi: 10.1111/j.1349-7006.2008.00951.x.